194 related articles for article (PubMed ID: 29416748)
1. SIRT1 contributes to neuroendocrine differentiation of prostate cancer.
Ruan L; Wang L; Wang X; He M; Yao X
Oncotarget; 2018 Jan; 9(2):2002-2016. PubMed ID: 29416748
[TBL] [Abstract][Full Text] [Related]
2. CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer.
Wen YC; Tram VTN; Chen WH; Li CH; Yeh HL; Thuy Dung PV; Jiang KC; Li HR; Huang J; Hsiao M; Chen WY; Liu YN
Cell Death Dis; 2023 May; 14(5):304. PubMed ID: 37142586
[TBL] [Abstract][Full Text] [Related]
3. AMPK/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells.
Natani S; Dhople VM; Parveen A; Sruthi KK; Khilar P; Bhukya S; Ummanni R
Biochim Biophys Acta Mol Cell Res; 2021 Sep; 1868(10):119085. PubMed ID: 34171447
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer.
Wu C; Huang J
J Biol Chem; 2007 Feb; 282(6):3571-83. PubMed ID: 17148458
[TBL] [Abstract][Full Text] [Related]
5. Human ASH-1 promotes neuroendocrine differentiation in androgen deprivation conditions and interferes with androgen responsiveness in prostate cancer cells.
Rapa I; Volante M; Migliore C; Farsetti A; Berruti A; Vittorio Scagliotti G; Giordano S; Papotti M
Prostate; 2013 Aug; 73(11):1241-9. PubMed ID: 23657976
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation-induced elevated nuclear SIRT1 promotes prostate tumor cell survival by reactivation of AR signaling.
Huang SB; Thapa D; Munoz AR; Hussain SS; Yang X; Bedolla RG; Osmulski P; Gaczynska ME; Lai Z; Chiu YC; Wang LJ; Chen Y; Rivas P; Shudde C; Reddick RL; Miyamoto H; Ghosh R; Kumar AP
Cancer Lett; 2021 May; 505():24-36. PubMed ID: 33617947
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
[TBL] [Abstract][Full Text] [Related]
8. Increased Expression of AKT3 in Neuroendocrine Differentiated Prostate Cancer Cells Alters the Response Towards Anti-Androgen Treatment.
Wiesehöfer M; Czyrnik ED; Spahn M; Ting S; Reis H; Dankert JT; Wennemuth G
Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33540707
[TBL] [Abstract][Full Text] [Related]
9. SIRT1 inhibition-induced senescence as a strategy to prevent prostate cancer progression.
Huang SB; Rivas P; Yang X; Lai Z; Chen Y; Schadler KL; Hu M; Reddick RL; Ghosh R; Kumar AP
Mol Carcinog; 2022 Jul; 61(7):702-716. PubMed ID: 35452563
[TBL] [Abstract][Full Text] [Related]
10. Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.
Enriquez C; Cancila V; Ferri R; Sulsenti R; Fischetti I; Milani M; Ostano P; Gregnanin I; Mello-Grand M; Berrino E; Bregni M; Renne G; Tripodo C; Colombo MP; Jachetti E
Cancer Res; 2021 Aug; 81(16):4257-4274. PubMed ID: 34185677
[TBL] [Abstract][Full Text] [Related]
11. Human ASH1 expression in prostate cancer with neuroendocrine differentiation.
Rapa I; Ceppi P; Bollito E; Rosas R; Cappia S; Bacillo E; Porpiglia F; Berruti A; Papotti M; Volante M
Mod Pathol; 2008 Jun; 21(6):700-7. PubMed ID: 18311112
[TBL] [Abstract][Full Text] [Related]
12. The Apoptotic and Anti-Warburg Effects of Brassinin in PC-3 Cells via Reactive Oxygen Species Production and the Inhibition of the c-Myc, SIRT1, and β-Catenin Signaling Axis.
Kwon HH; Ahn CH; Lee HJ; Sim DY; Park JE; Park SY; Kim B; Shim BS; Kim SH
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762214
[TBL] [Abstract][Full Text] [Related]
13. A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers.
Elhasasna H; Khan R; Bhanumathy KK; Vizeacoumar FS; Walke P; Bautista M; Dahiya DK; Maranda V; Patel H; Balagopal A; Alli N; Krishnan A; Freywald A; Vizeacoumar FJ
Cells; 2022 Jul; 11(14):. PubMed ID: 35883689
[TBL] [Abstract][Full Text] [Related]
14. Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46.
Liu YN; Niu S; Chen WY; Zhang Q; Tao Y; Chen WH; Jiang KC; Chen X; Shi H; Liu A; Li J; Li Y; Lee YC; Zhang X; Huang J
Clin Cancer Res; 2019 Jul; 25(13):4128-4140. PubMed ID: 30962287
[TBL] [Abstract][Full Text] [Related]
15. Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer.
Chen WY; Thuy Dung PV; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Hsiao M; Huang J; Wen YC; Liu YN
Redox Biol; 2023 Jun; 62():102686. PubMed ID: 36963289
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine differentiation in prostate cancer.
Sun Y; Niu J; Huang J
Am J Transl Res; 2009 Feb; 1(2):148-62. PubMed ID: 19956427
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression.
Xie Y; Ning S; Hu J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1813-1823. PubMed ID: 35633416
[TBL] [Abstract][Full Text] [Related]
19. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention.
Nouri M; Ratther E; Stylianou N; Nelson CC; Hollier BG; Williams ED
Front Oncol; 2014; 4():370. PubMed ID: 25566507
[TBL] [Abstract][Full Text] [Related]
20. Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival.
Giordano F; Naimo GD; Nigro A; Romeo F; Paolì A; De Amicis F; Vivacqua A; Morelli C; Mauro L; Panno ML
Drug Des Devel Ther; 2019; 13():4265-4274. PubMed ID: 31908413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
